Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherBasic Science (Animal or Phantoms)

Utility of 211At-trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically-relevant Mouse Model

Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and SUMITAKA HASEGAWA
Journal of Nuclear Medicine February 2021, jnumed.120.249300; DOI: https://doi.org/10.2967/jnumed.120.249300
Huizi Keiko Li
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukie Morokoshi
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Kodaira
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamon Kusumoto
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsuyuki Minegishi
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Kanda
2 Saitama Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kotaro Nagatsu
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUMITAKA HASEGAWA
1 National Institutes for Quantum and Radiological Science and Technology, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A liver metastasis from a primary gastric cancer (LMGC) is relatively common and results in an extremely poor prognosis due to a lack of effective therapeutics. We here demonstrate in a clinically-relevant mouse model that an α-radioimmunotherapy (α-RIT) approach with astatine-211-labeled-trastuzumab (211At-trastuzumab) has efficacy against LMGCs that are positive for human epidermal growth factor receptor 2 (HER2). Methods: 211At was produced in a cyclotron via a 209Bi (α, 2n) 211At reaction. 211At-trastuzumab was subsequently generated using a single-step labelling method. NCI-N87 cells (HER2-positive human GC cells) carrying a luciferase gene were intrasplenically transplanted into severe combined immunodeficiency mice to generate a HER2-positive LMGC model. A bio-distribution study was then conducted through the intravenous injection of 211At-trastuzumab (1 MBq) into these LMGC xenograft mice. In parallel with this experimental therapy, PBS, intact trastuzumab or 211At-non-specific human IgG (1MBq) were injected into control groups. The therapeutic efficacy was evaluated by monitoring tumor changes by chemiluminescence imaging. Monitoring of body weights, white blood cell counts, and serum markers of tissue damage were conducted at regular intervals. Microdosimetry using a CR39 plastic detector was also performed. Results: The biodistribution analysis revealed an increased uptake of 211At-trastuzumab in the metastasized tumors that reached approximately 12% of the injected dose per gram of tissue (%ID/g) at 24 hours. In contrast, its uptake to the surrounding liver was about 4%ID/g. The LMGCs in the mouse model reduced dramatically at 1 week after the single systemic injection of 211At-trastuzumab. No recurrences were observed in six of eight mice treated with this single injection and their survival time was significantly prolonged compared to the control groups, including the animals treated with 211At-non-specific antibodies. No severe toxicities or abnormalities in terms of body weight, white blood cell number, liver function, or kidney parameters were observed in the 211At-trastuzumab group. Microdosimetric studies further revealed that 211At-trastuzumab had been delivered at an 11.5- fold higher dose to the LMGC lesions compared to the normal liver. Conclusion: α-RIT with 211At-trastuzumab has considerable potential as an effective and safe therapeutic option for LMGC.

  • Oncology: GI
  • Radionuclide Therapy
  • Radiopharmaceuticals
  • α-RIT
  • HER2
  • cancer metastasis
  • gastric cancer
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Utility of 211At-trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically-relevant Mouse Model
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Utility of 211At-trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically-relevant Mouse Model
Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu, SUMITAKA HASEGAWA
Journal of Nuclear Medicine Feb 2021, jnumed.120.249300; DOI: 10.2967/jnumed.120.249300

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Utility of 211At-trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically-relevant Mouse Model
Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu, SUMITAKA HASEGAWA
Journal of Nuclear Medicine Feb 2021, jnumed.120.249300; DOI: 10.2967/jnumed.120.249300
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Non-Human Primates
  • Synthesis and Preclinical Evaluation of 68Ga-labeled Adnectin, 68Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression
Show more Basic Science (Animal or Phantoms)

Similar Articles

Keywords

  • Oncology: GI
  • Radionuclide Therapy
  • radiopharmaceuticals
  • α-RIT
  • HER2
  • cancer metastasis
  • gastric cancer
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire